mTABLET ABI

MESI mTABLET ABI: Leading the Way in Peripheral Arterial Disease Screening

Introducing the MESI mTABLET ABI, a game-changer in cardiovascular diagnostics, specially designed for Australian healthcare. This innovative device offers a solution previously unavailable and enables general practices across the country to quickly and accurately detect Peripheral Arterial Disease.

Advanced ABI Testing with MESI mTABLET

Fast and Accurate Cardiovascular Health Assessments

Rapid ABI Measurement: Take advantage of the world's fastest ABI test for huge time savings in consultations without compromising on reading accuracy.
Wireless Convenience: Utilising innovative 3CUFF technology, the MESI mTABLET ABI allows for simultaneous brachial and ankle pressure measurement without the tangles of cables.
Seamless System Integration: It integrates in a complementary manner with existing EHR systems in various clinics across Australia. This avoids disruptions in workflows.

Designed for Comprehensive Cardiovascular Care

Varied applications: This include that the MESI mTABLET ABI is not intended for screening for PAD only but finds its ideal application in primary care, vascular medicine, and management of chronic diseases, hence finding its place in the versatile toolset within the Australian healthcare landscape.
Expandable Diagnostics: Expand your diagnostic circle with other modalities, including ECG, spirometry, and blood pressure on one platform.

Transforming Patient Care in Australia

Early detection of PAD holds significant implications for the management of cardiovascular risk, especially among the growing aged population in Australia.
Efficient Practice: This streamlines the diagnosis process, hence allowing more patients to be consulted within less time.
Improved Patient Outcomes: Early diagnosis and symptom-free detection result in better management of vascular health, thereby contributing to overall patient care.
Cost-effective: reduces referrals to specialist vascular services, which keeps costs lower for the patients and practices involved.

Join the Revolution in Cardiovascular Screening

The MESI mTABLET ABI represents a significant advancement in the point-of-care diagnostics available to Australian GPs and healthcare professionals. It empowers providers to deliver high-quality, evidence-based cardiovascular care with greater efficiency and accuracy.

Early detection of PAD holds significant implications for the management of cardiovascular risk, especially among the growing aged population in Australia.
Efficient Practice: This streamlines the diagnosis process, hence allowing more patients to be consulted within less time.
Improved Patient Outcomes: Early diagnosis and symptom-free detection result in better management of vascular health, thereby contributing to overall patient care.
Cost-effective: reduces referrals to specialist vascular services, which keeps costs lower for the patients and practices involved.

CALL US TODAY!

For more information on how the MESI mTABLET can benefit your Australian general practice, please contact your Internal Sales Professional or our friendly Customer Service team on 1300 557 651.

What device are you interested in? MESI mTABLET ECG MESI mTABLET SPIRO MESI mTABLET ABI

Full name

Business Name

Email Address

Phone

EBOS Group Australia Pty Ltd (“Vital Medical Supplies”) collects your personal information (PI) for the purposes of responding to your query, including to provide you with information about Vital Medical Supplies products and services. For these purposes, Vital Medical Supplies may disclose your PI to our related bodies corporate and third parties contracted to us. If you do not provide this information, we may not be able to respond to your query. Our Privacy Policy contains further information on how we collect, hold and use your PI.

I consent to my information being collected and have read and understood the Privacy Policy Yes

Word verification An error has occurred while getting captcha image